Annals of Nutrition and Metabolism

Original Paper

Effect of Antiepileptic Therapy on Serum 25(OH)D3 and 24,25(OH)2D3 Levels in Epileptic Children

He X.a, b · Jiang P.a, c · Zhu W.a · Xue Y.a, b · Li H.a · Dang R.a, c · Cai H.a · Tang M.a · Zhang L.a · Wu Y.a

Author affiliations

aInstitute of Clinical Pharmacy and Pharmacology, Second Xiangya Hospital, and bSchool of Pharmaceutical Sciences, Central South University, Changsha, and cDepartment of Pharmacy, Jining First People's Hospital, Jining, China

Keywords: Vitamin D deficiencyEpilepsyAntiepileptic drugsChildren

Related Articles for ""
Ann Nutr Metab 2016;68:119-127
https://doi.org/10.1159/000443535

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: October 04, 2015
Accepted: December 10, 2015
Published online: January 27, 2016
Issue release date: February 2016

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 5

ISSN: 0250-6807 (Print)
eISSN: 1421-9697 (Online)

For additional information: https://www.karger.com/ANM

Abstract

Background: Vitamin D deficiency is not only associated with the adverse effects of chronic treatment with antiepileptic drugs (AEDs), but also with epilepsy. Although emerging evidence suggests that AEDs can accelerate the vitamin D catabolism, resulting in suboptimal vitamin D status, there are a limited number of studies examining the vitamin D status in epileptic patients, especially in first-episode or AEDs-naïve children. Methods: Determined with high-performance liquid chromatography-tandem mass spectrometry, circulating 25(OH)D3 and 24,25(OH)2D3 levels, and 24,25(OH)2D3:25(OH)D3 ratio were compared between AEDs-treated epileptic (n = 363) and control (n = 159) children. To further figure out whether the patients were in a vitamin D deficient prone state even before treatment, epileptic children before their initiation of treatment (n = 51) were enrolled into a follow-up study. Results: A significant decrease of 25(OH)D3 and 24,25(OH)2D3 levels, but a significant increase of 24,25(OH)2D3:25(OH)D3 ratio was observed in epileptic children, compared with controls. Baseline 25(OH)D3, 24,25(OH)2D3 and 24,25(OH)2D3:25(OH)D3 ratio in the follow-up group were similar to those in controls, but significantly changed with 2 months of AED therapy. Conclusions: Disturbed vitamin D levels were possibly the consequence of AED therapy, rather than the contributing factor of epilepsy. Collectively, circulating vitamin D levels should be monitored and corrected in AEDs-treated epileptic children.

© 2016 S. Karger AG, Basel



Related Articles:

References

  1. Kesby JP, Eyles DW, Burne TH, McGrath JJ: The effects of vitamin D on brain development and adult brain function. Mol Cell Endocrinol 2011;347:121-127.
  2. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D: Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-240.
  3. Kocovska E, Fernell E, Billstedt E, Minnis H, Gillberg C: Vitamin D and autism: clinical review. Res Dev Disabil 2012;33:1541-1550.
  4. Crews M, Lally J, Gardner-Sood P, Howes O, Bonaccorso S, Smith S, Murray RM, Di Forti M, Gaughran F: Vitamin D deficiency in first episode psychosis: a case-control study. Schizophr Res 2013;150:533-537.
  5. Jiang P, Zhang WY, Li HD, Cai HL, Liu YP, Chen LY: Stress and vitamin D: altered vitamin D metabolism in both the hippocampus and myocardium of chronic unpredictable mild stress exposed rats. Psychoneuroendocrinology 2013;38:2091-2098.
  6. Groves NJ, McGrath JJ, Burne TH: Vitamin D as a neurosteroid affecting the developing and adult brain. Annu Rev Nutr 2014;34:117-141.
  7. Cashman KD, Hayes A, Galvin K, Merkel J, Jones G, Kaufmann M, Hoofnagle AN, Carter GD, Durazo-Arvizu RA, Sempos CT: Significance of serum 24,25-dihydroxyvitamin D in the assessment of vitamin d status: a double-edged sword? Clin Chem 2015;61:636-645.
  8. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, Thummel KE: Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 2006;69:56-65.
  9. Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, Thummel KE: Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006;116:1703-1712.
  10. Norman AW, Okamura WH, Bishop JE, Henry HL: Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R,25(OH)2-vitamin D3. Mol Cell Endocrinol 2002;197:1-13.
  11. Curtis KM, Aenlle KK, Roos BA, Howard GA: 24R,25-dihydroxyvitamin D3 promotes the osteoblastic differentiation of human mesenchymal stem cells. Mol Endocrinol 2014;28:644-658.
  12. St-Arnaud R: CYP24A1-deficient mice as a tool to uncover a biological activity for vitamin D metabolites hydroxylated at position 24. J Steroid Biochem Mol Biol 2010;121:254-256.
  13. Wagner D, Hanwell HE, Schnabl K, Yazdanpanah M, Kimball S, Fu L, Sidhom G, Rousseau D, Cole DE, Vieth R: The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation. J Steroid Biochem Mol Biol 2011;126:72-77.
  14. Gniatkowska-Nowakowska A: Fractures in epilepsy children. Seizure 2010;19:324-325.
  15. Nettekoven S, Strohle A, Trunz B, Wolters M, Hoffmann S, Horn R, Steinert M, Brabant G, Lichtinghagen R, Welkoborsky HJ, Tuxhorn I, Hahn A: Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr 2008;167:1369-1377.
  16. Baek JH, Seo YH, Kim GH, Kim MK, Eun BL: Vitamin D levels in children and adolescents with antiepileptic drug treatment. Yonsei Med J 2014;55:417-421.
  17. Menon B, Harinarayan CV: The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism - a longitudinal study. Seizure 2010;19:153-158.
  18. Hollo A, Clemens Z, Lakatos P: Epilepsy and vitamin D. Int J Neurosci 2014;124:387-393.
  19. Nicolaidou P, Georgouli H, Kotsalis H, Matsinos Y, Papadopoulou A, Fretzayas A, Syriopoulou V, Krikos X, Karantana A, Karpathios T: Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol 2006;21:205-209.
  20. Verrotti A, Agostinelli S, Coppola G, Parisi P, Chiarelli F: A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. Eur J Neurol 2010;17:232-237.
  21. Dang R, Jiang P, Cai H, Li H, Guo R, Wu Y, Zhang L, Zhu W, He X, Liu Y, Xu P: Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: involvement of the INSIG/SREBP pathway. Eur Neuropsychopharmacol 2015;25:1239-1247.
  22. Fong CY, Riney CJ: Vitamin D deficiency among children with epilepsy in South Queensland. J Child Neurol 2014;29:368-373.
  23. Siegel A, Malkowitz L, Moskovits MJ, Christakos S: Administration of 1,25-dihydroxyvitamin D3 results in the elevation of hippocampal seizure threshold levels in rats. Brain Res 1984;298:125-129.
  24. Borowicz KK, Morawska M, Furmanek-Karwowska K, Luszczki JJ, Czuczwar SJ: Cholecalciferol enhances the anticonvulsant effect of conventional antiepileptic drugs in the mouse model of maximal electroshock. Eur J Pharmacol 2007;573:111-115.
  25. Hollo A, Clemens Z, Kamondi A, Lakatos P, Szucs A: Correction of vitamin D deficiency improves seizure control in epilepsy: a pilot study. Epilepsy Behav 2012;24:131-133.
  26. Christiansen C, Rodbro P, Sjo O: ‘Anticonvulsant action' of vitamin D in epileptic patients? A controlled pilot study. Br Med J 1974;2:258-259.
  27. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia 1989;30:389-399.
  28. Aronov PA, Hall LM, Dettmer K, Stephensen CB, Hammock BD: Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2008;391:1917-1930.
  29. Pearce SH, Cheetham TD: Diagnosis and management of vitamin D deficiency. BMJ 2010;340:b5664.
  30. Lips P: Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 2007;103:620-625.
  31. Cebeci AN, Ekici B: Epilepsy treatment by sacrificing vitamin D. Expert Rev Neurother 2014;14:481-491.
  32. Kalueff AV, Minasyan A, Keisala T, Kuuslahti M, Miettinen S, Tuohimaa P: Increased severity of chemically induced seizures in mice with partially deleted vitamin D receptor gene. Neurosci Lett 2006;394:69-73.
  33. Sonmez FM, Donmez A, Namuslu M, Canbal M, Orun E: Vitamin D deficiency in children with newly diagnosed idiopathic epilepsy. J Child Neurol 2015;30:1428-1432.
  34. Procopio M, Marriott PK, Davies RJ: Seasonality of birth in epilepsy: a Southern hemisphere study. Seizure 2006;15:17-21.
  35. Perret EV, von Elm E, Lienert C, Steinlin M: Infantile spasms: does season influence onset and long-term outcome? Pediatr Neurol 2010;43:92-96.
  36. Clemens Z, Holló A, Kelemen A, Rásonyi G, Fabó D, Halász P, Janszky J, Szűcs A: Seasonality of epileptic seizures. J Neurol Transl Neurosci 2013;1:1016.
  37. Kalueff AV, Minasyan A, Tuohimaa P: Anticonvulsant effects of 1,25-dihydroxyvitamin D in chemically induced seizures in mice. Brain Res Bull 2005;67:156-160.
  38. Geerts A, Arts WF, Stroink H, Peeters E, Brouwer O, Peters B, Laan L, van Donselaar C: Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch study of epilepsy in childhood. Epilepsia 2010;51:1189-1197.
  39. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P, Vilarem MJ: Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005;115:177-186.
  40. Sawada N, Kusudo T, Sakaki T, Hatakeyama S, Hanada M, Abe D, Kamao M, Okano T, Ohta M, Inouye K: Novel metabolism of 1 alpha,25-dihydroxyvitamin D3 with C24-C25 bond cleavage catalyzed by human CYP24a1. Biochemistry 2004;43:4530-4537.
  41. Nallani SC, Glauser TA, Hariparsad N, Setchell K, Buckley DJ, Buckley AR, Desai PB: Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 2003;44:1521-1528.
  42. Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM: Prevention of bone loss and vertebral fractures in patients with chronic epilepsy - antiepileptic drug and osteoporosis prevention trial. Epilepsia 2013;54:1997-2004.
  43. Borusiak P, Langer T, Heruth M, Karenfort M, Bettendorf U, Jenke AC: Antiepileptic drugs and bone metabolism in children: data from 128 patients. J Child Neurol 2013;28:176-183.
  44. Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, Maeda H, Satoh K: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449.
  45. Guo CY, Ronen GM, Atkinson SA: Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42:1141-1147.
  46. Cansu A, Yesilkaya E, Serdaroglu A, Hirfanoglu TL, Camurdan O, Gulbahar O, Gucuyener K, Cinaz P: Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 2008;39:266-271.
  47. Teagarden DL, Meador KJ, Loring DW: Low vitamin D levels are common in patients with epilepsy. Epilepsy Res 2014;108:1352-1356.
  48. Vrzal R, Doricakova A, Novotna A, Bachleda P, Bitman M, Pavek P, Dvorak Z: Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia? Toxicol Lett 2011;200:146-153.
  49. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P: Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007;35:1032-1041.
  50. Krishnamoorthy G, Nair R, Sundar U, Kini P, Shrivastava M: Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: a prospective study. Neurol India 2010;58:213-219.
  51. Zerwekh JE, Homan R, Tindall R, Pak CY: Decreased serum 24,25-dihydroxyvitamin D concentration during long-term anticonvulsant therapy in adult epileptics. Ann Neurol 1982;12:184-186.
  52. Jones G, Prosser DE, Kaufmann M: 25-Hydroxyvitamin D-24-hydroxylase (CYP24a1): its important role in the degradation of vitamin D. Arch Biochem Biophys 2012;523:9-18.
  53. Berg AH, Powe CE, Evans MK, Wenger J, Ortiz G, Zonderman AB, Suntharalingam P, Lucchesi K, Powe NR, Karumanchi SA, Thadhani RI: 24,25-Dihydroxyvitamin D3 and vitamin D status of community-dwelling black and white Americans. Clin Chem 2015;61:877-884.
  54. Beerhorst K, van der Kruijs SJ, Verschuure P, Tan IY, Aldenkamp AP: Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. J Neurol Sci 2013;331:19-25.
  55. Basatemur E, Sutcliffe A: Incidence of hypocalcemic seizures due to vitamin D deficiency in children in the United Kingdom and Ireland. J Clin Endocrinol Metab 2015;100:E91-E95.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: October 04, 2015
Accepted: December 10, 2015
Published online: January 27, 2016
Issue release date: February 2016

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 5

ISSN: 0250-6807 (Print)
eISSN: 1421-9697 (Online)

For additional information: https://www.karger.com/ANM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2016, Vol.68, No. 2

February 2016

Article

Recommend This
Additional Information

X.H. and P.J. contributed equally to this work.
TOP